Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone in Heart Failure with Insulin Resistance
NCT00064727Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing Rosiglitazone with Placebo (2 arms). Primary endpoints: Safety of administration at 6 months and Modulation in contractile function at 6 months. Started Jul 2003; status: completed.
02
Drugs
rosiglitazone
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00064727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00064727.